Drug Profile
Research programme: cardiovascular disorders therapies - Chronogen/Tripos
Alternative Names: Acute ROS modulators - Chronogen; CLK-1 inhibitors - Chronogen; Lipid/LDL modulators - ChronogenLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Chronogen; Tripos
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cardiovascular disorders; Lipid metabolism disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in Canada
- 16 Jul 2016 No recent reports of development identified for preclinical development in Lipid-metabolism-disorders in Canada
- 29 Aug 2005 Preclinical trials in Lipid metabolism disorders in Canada (unspecified route)